Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update
1. Alector's INFRONT-3 trial failed to meet primary endpoint for latozinemab. 2. Significant biomarker effects observed, but no clinical benefit found. 3. Company plans a 49% workforce reduction for resource realignment. 4. Dr. Sara Kenkare-Mitra resigns; transition to occur by December 2025. 5. Alector maintains strong cash reserves expected to last through 2027.